Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Biovance Capital is a venture capital firm based in Lisbon, Portugal, founded in 2023. The firm focuses on early-stage investments in biopharma companies across Europe, particularly in Southern Europe. Biovance Capital is fully team-owned and operates with a strong network that includes research institutes, incubators, and accelerators. The firm was established to support the development of innovative therapies in various therapeutic areas and modalities.
As of now, Biovance Capital manages a fund size of $57 million, which is aimed at fostering the growth of promising biotech companies. The firm has a clear investment strategy that targets seed and Series A rounds, seeking to identify companies with strong preclinical models and patented or patentable assets. Biovance Capital's inaugural investment was in Mondego Bio, a Portuguese oncology startup, showcasing its commitment to the biopharma sector.
Biovance Capital operates from two office locations in Portugal: Lisbon and Porto. The firm collaborates with notable limited partners, including the European Investment Fund (EIF) and BIAL, Portugal's largest pharmaceutical company. This collaboration enhances its ability to support portfolio companies in achieving their development goals.
Biovance Capital primarily invests in seed and Series A rounds of early-stage biopharma companies, with a strong emphasis on Southern Europe. The firm targets companies that are developing therapeutics with robust preclinical models and patented or patentable assets. Biovance Capital emphasizes sectors that have potential for venture capital, mergers and acquisitions, or initial public offerings. This focus ensures that the companies they invest in operate within a favorable regulatory environment and have clear reimbursement policies.
The firm seeks to identify biotech companies that demonstrate promising therapeutic candidates and clear regulatory pathways. Biovance Capital's investment strategy is designed to support the development of transformative therapies, leveraging its extensive network in the biopharma sector. The firm is particularly interested in companies that can navigate the complexities of the regulatory landscape effectively.
Biovance Capital's portfolio currently includes one notable company:
This inaugural investment highlights Biovance Capital's commitment to supporting early-stage biopharma companies that are developing groundbreaking therapies. The firm is actively deploying its capital to identify and invest in additional promising startups in the biopharma sector.
Ricardo Perdigão Henriques, PhD - Managing Partner. He has a background in biomedical science and is educated at Harvard Medical School and MIT.
João Incio, MD, PhD - General Partner. He brings medical expertise and experience in the biopharma sector.
André Albergaria, PhD - Principal. He has over 20 years of experience fostering industry-academia collaborations in Portugal's largest health research institute.
Peter Villax - Non-Executive Partner. He also serves as Chairman at Bionova Capital.
João Botelho - CFO. He oversees the financial operations of the firm.
Hannah Franklin, PhD - Associate. She contributes her scientific expertise to the investment process.
Raquel Melo - Financial Manager. She manages financial reporting and analysis.
Yunyun Sun, PhD - Fellow. She supports research and analysis efforts.
Ana Agostinho - Office Manager. She oversees office operations.
Beatriz Martins Ferreira - Compliance Officer. She ensures regulatory compliance.
Ana Pinheiro - External Sustainability Consultant. She advises on sustainability practices.
When pitching to Biovance Capital, include detailed information about your therapeutic candidates, preclinical data, and any existing patents or patent applications. Highlight the regulatory pathway and potential market opportunities.
In 2023, Biovance Capital announced the first closing of its fund, reaching EUR 51 million, and later secured additional investment from BIAL, bringing the total fund size to EUR 57 million. This fund is focused on early-stage biopharma investments across Europe.
Biovance Capital led the Series A funding round for Mondego Bio, its inaugural investment, alongside OrbiMed and Torrey Pines. Mondego Bio is a Portuguese oncology startup that focuses on innovative cancer treatments.
The firm has been actively promoting its mission to support transformative therapies in the biopharma sector, collaborating with a network of research institutes, incubators, and accelerators.
What are Biovance Capital's investment criteria?
Biovance Capital invests in seed and Series A rounds of early-stage biopharma companies, primarily in Southern Europe. The firm looks for companies developing therapeutics with strong preclinical models and patented or patentable assets.
How can founders apply or pitch to Biovance Capital?
Founders interested in pitching to Biovance Capital should prepare a detailed presentation that outlines their business model, therapeutic candidates, and regulatory pathways. Specific application forms or portals have not been disclosed.
What makes Biovance Capital different from other venture capital firms?
Biovance Capital differentiates itself through its focus on early-stage biopharma investments in Southern Europe and its extensive network that includes research institutions and accelerators. This network provides portfolio companies with valuable resources and support.
What is the geographic scope of Biovance Capital's investments?
The firm primarily focuses on investments in Southern Europe but is open to opportunities across Europe. This geographic focus allows Biovance Capital to tap into emerging biotech hubs in the region.
What is the typical check size for investments made by Biovance Capital?
Biovance Capital typically invests between EUR 1.5 million and EUR 6 million per investment, depending on the stage and potential of the company.
What kind of post-investment involvement does Biovance Capital have?
Biovance Capital adds value to its portfolio companies through its extensive network in the biopharma sector and expertise in navigating regulatory pathways. The team comprises experienced professionals who actively support portfolio companies in achieving their development goals.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.